Skip to main content

Zentalis Pharmaceuticals Llc (NASDAQ: ZNTL) — Company Overview, News & Financial Data

Zentalis Pharmaceuticals Llc logo
ZNTL Zentalis Pharmaceuticals Llc
Zentalis Pharmaceuticals Llc primary media
Company profile

Zentalis Pharmaceuticals Llc

Zentalis Pharmaceuticals (NASDAQ:ZNTL) is a biopharmaceutical company focused on discovering and developing small molecule therapeutics aimed at addressing various forms of cancer. Leveraging its proprietary technology platforms, Zentalis is working on a pipeline of oncology compounds with the potential to improve the lives of patients by targeting the molecular and genetic drivers of cancer. The company's objective is to push the boundaries of what is possible in cancer treatment by creating medicines that offer new hope and better outcomes. With a focus on rigorous science and a commitment to innovation, Zentalis Pharmaceuticals strives to bring forward novel therapies that address unmet medical needs in the oncology space.

Snapshot

Public USOwnership
2014Year founded
173Employees
New York, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
New York City, US

Products and/or services of Zentalis Pharmaceuticals Llc

  • Development of ZN-c3, a Wee1 inhibitor for treating solid tumors.
  • Investigation of ZN-d5, a BCL-2 inhibitor aimed at blood cancers.
  • Research on ZN-c5, an oral SERD for estrogen receptor-positive breast cancer.
  • Exploration of combination therapies using their proprietary compounds to enhance cancer treatment efficacy.
  • Advancing ZN-e4, a candidate for treating non-small cell lung cancer.
  • Collaboration on biomarker-driven projects to personalize and improve cancer treatment outcomes.

Zentalis Pharmaceuticals Llc executive team

  • Julie M. EastlandCEO, President & Director
  • James B. BucherChief Legal Officer & Corporate Secretary
  • Ingmar BrunsChief Medical Officer
  • Vincent A. VultaggioSVP of Finance & Principal Accounting Officer
  • Robert J. DiVastoChief Technical Officer
  • Wendy ChangChief People Officer
  • Haibo WangChief Business Officer
  • Rajesh IsraniExecutive VP of Regulatory Affairs & Medical Writing
  • Henry GuSenior VP & Head of Intellectual Property
  • Sarah KellySenior Vice President of Commercial Strategy

Recent announcements

What Zentalis Pharmaceuticals Llc (ZNTL) has told the market, newest first.

Key financials

Reported results for Zentalis Pharmaceuticals Llc, in USD.

Market cap
133.6M
Revenue (TTM)
26.9M
P/E ratio
—
EPS (diluted, TTM)
-1.9
Dividend yield
—
Profit margin
0.0%
Zentalis Pharmaceuticals Llc annual revenue and income
Fiscal year endRevenueOperating incomeNet income
0-152.8M-137.1M
67.4M-191.2M-165.8M
0-299.5M-292.2M
0-227.3M-236.8M